Screening asymptomatic people at high risk for hepatitis C: The case for

British Medical Journal

Volumn 312, Issue 7042, 1996, Pages 1347-1348

  Seymour, Carol A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNOBLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCREENING; UNITED STATES;

HEPATITIS C; HUMANS; MASS SCREENING; RISK-TAKING; TREATMENT OUTCOME;

EID: 0029979894     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Moradpour D, Wands JR. Understanding Hepatitis B infection [editorial]. J Engl J Med 1995;332:1092-3.
2. Van der Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994;344:1475-9.
3. Alter HJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
4. Terrault N, Wright T. Interferon and hepatitis C. N Engl J Med 1995;332:1509-11.
5. Ascher NL, Lake RJ, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20:245-275.
6. Bresters D, Mauser-Bunschoten EP, Reesink HW, Roosendale G, van der Poel CL. Sexual transmission of hepatitis C. Lancet 1993;342:210-1.
7. Uyttendaele S, Claeys H, Mertens W, Verhaert H, Vermylen C. Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994; 6:122-9.
8. Zaaijer HL, Cuypers HT, Reesink HW, Winkel IN, Gerken G, Lelie PN. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993;341:722-4.
9. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap P-L, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994;19:13-8.
10. Cuckle HS, Richardson GA, Sheldon TA, Quirke P. Cost effectiveness of antenatal screening for cystic fibrosis. BMJ 1995;311:1460-3.
11. Goodrick MJ, Gray SF, Rouse AM, Waters AJ, Anderson NA. Hepatitis C (HCV) positive blood donors in south-west England: case control study. Transfusion Med 1994;4:113-9.
12. Maclennan S, Moore MC, Hewitt PE, Nicoles S, Barbara JAJ. A study of anti-hepatitis C positive blood donors: the first year of screening. Transfusion Med 1994;4:130-3.
13. Watson JP, Brind AM, Chapman CE, Bates CL, Gould FK, Johnson SJ, et al. Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut 1996;38:269-276.
14. Bruno S, Rossi S, Petroni ML, Villa E, Zuin M, Podda M. Normal aminotransferase concentration in patients with antibodies to hepatitis C virus. BMJ 1994;308:697.
15. Seymour CA. Asymptomatic infection with hepatitis C virus [editorial]. BMJ 1994;308:670-1.
16. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991;13:192-9.
17. Saracco G, Rossina F, Abate ML, Carucci P, Solinas A, Chianduss L, et al. Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. Hepatology 1993;18:1300-5.
18. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C virus infection. N Engl J Med 1995;332:1463-6.
19. Polynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long term treatment of chronic non-A non-B hepatitis. N Engl J Med 1995;332:1457-62.
20. Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994;160:268-72.